- Open Access
Cost analysis of chronic obstructive pulmonary disease (COPD): a systematic review
Health Economics Review volume 11, Article number: 31 (2021)
Chronic Obstructive Pulmonary Disease (COPD) is a treatable disease with a high prevalence, and high morbidity associated with significant socioeconomic costs.
To carry out a systematic review of the literature to analyze the main cost studies associated with COPD, in order to determine the main factors that influence the costs of the disease.
Searches were conducted in PubMed, SCOPUS and Web of Science databases for cost studies on COPD published in English, between the years 2015 and 2020. The search terms were “COPD” OR “pulmonary disease, chronic obstructive”, “cost*” OR “cost of illness”, “economic impact” AND “burden of disease”. The inclusion criteria included the identification of reported cost of the disease, economic burden, medical care expenses or use resources for COPD, the methodology used, data sources, and variables studied.
18 publications were analyzed: 17 included direct health costs, 6 included direct non-medical costs, 12 analyzed indirect costs and two reported intangible costs. Most of the studies reported data for developed and European countries, with direct costs being the most studied. Trends were observed in multiple studies of direct and healthcare costs for European countries measured by patient and year, where the higher costs were associated with more severe COPD and a frequent history of exacerbations. The highest costs reported corresponded to hospitalizations and the associated pharmacological treatment. The importance of the loss of productivity and premature retirement within the profile of the COPD patient was also highlighted as the main generator of indirect costs of the disease.
COPD generates substantial costs for the health system, mainly related to moderate to severe stages and the exacerbations and complications entailed. It is important to strengthen health systems with monitoring, evaluation and health education models that allow these patients to remain stable to avoid decompensation and subsequent hospitalizations.
According to the Global Initiative for Chronic Obstructive Lung Disease (GOLD), COPD is defined as “a common, preventable, and treatable disease that is characterized by persistent respiratory symptoms and airflow limitation that is due to airway and/or alveolar abnormalities usually caused by significant exposure to noxious particles or gases” , tobacco being the main cause detected .
The clinical manifestations of this heterogeneous disease are generally identified in people between the age of 40–50 years, although symptoms may appear earlier. The main symptoms associated with the disease are dyspnea, chronic cough, and expectoration. These symptoms can often mislead the diagnosis, as they can be confused with other chronic respiratory pathologies with a similar course, such as asthma. The literature generally identifies four phenotypes or clinical forms within the disease that determine different treatments: non-acute, with emphysema or chronic bronchitis, COPD-Asthma, acute with emphysema and acute with chronic bronchitis .
The natural history of COPD includes episodes of exacerbation, which become common in the moderate and severe stages of the disease. These episodes increase morbidity-mortality, health system resource utilization (increased costs) and lead to loss of productivity and deterioration of the health-related quality of life (HRQoL) of the patients who suffer from them [2, 3]. Exacerbations are defined as an acute episode of clinical instability characterized by a worsening of respiratory symptoms” . Patients with COPD experience an average of one to four exacerbations per year; however, the intensity and duration varies from patient to patient, making it difficult to quantitatively estimate their exact consequences . They are mainly related to respiratory infections or environmental stressors, but sometimes they can also be linked to the presence of other concomitant pathologies, which can produce a greater aggravation of symptoms and, consequently, greater difficulty for the patient’s recovery .
Epidemiologically, COPD is identified as the third leading cause of death worldwide, besides representing one of the main causes of increased morbidity, inducing an economic and social burden that is currently on the rise. The morbidity and mortality identified vary from one country to another and from one population group to another, which is why the existing prevalence data widely differ .
The main usefulness of cost-of-illness studies is based on the identification and measurement of part of the financial impact of the disease, at the health, social and work levels, helping health system managers with limited budgets and resources to cover a set of unlimited needs and to make a cost-effective allocation between the investment options that exist and are presented to them in their day-to-day activity.
In the case of highly prevalent chronic diseases, it is essential to quantify the social and financial magnitude of the disease in all spheres (direct and indirect costs, health and non-medical costs, labor losses and intangible costs). This will improve the ability to design, prioritize, and apply preventive and health promotion measures, investments in public health or social policies and protocols and care guidelines in the most equitable and efficient way possible. Furthermore, this will also allow constant updating to prevent current practices from becoming obsolete, inefficient, and costly because they are not adapted to the reality of the disease.
Various international studies have been carried out to try to estimate the cost of COPD to society or to the health care system, in different manners and applied to different processes of the disease and with highly variable study designs, thus obtaining heterogeneous results. This variability in the methodology used by the different authors makes it difficult to extrapolate results and conclusions, which can lead to a failure to make the most appropriate and cost-effective decisions for managing a disease with an ever-increasing prevalence in society. In view of the wide variety of estimates, it is important to develop a guide that provides a homogeneous estimate and includes comparable data.
The principal aim of this systematic review was to identify the main factors that lead to increased costs in COPD patients.
A systematic review of the literature on COPD-associated cost studies was conducted and served as the basis for the design of the overall structure of this systematic review. The studies were identified and selected by conducting a literature search using three electronic databases: PubMed, SCOPUS, and Web of Science.
The terms included in the thesaurus of the National Library of Medicine of the United States (Medical Subject Headings, MeSH) were used: “COPD or “pulmonary disease, chronic obstructive”, “cost*” or “cost of illness”, “economic impact” and “burden of disease” in the title or abstract fields to retrieve potentially relevant publications in the last five years (January 1, 2015 to July 30, 2020). The search strategy was limited to publications made in English and Spanish. The results were complemented with a new review with free-text language with keywords of the present monograph and filtering in the last five years in the Google Scholar database after which 36 articles were selected (Table 1).
The inclusion criteria consisted of systematic review or original research, meeting the following conditions:
Reported cost of illness, economic burden, health care expenditures, or use of resources for COPD.
Development of the methodology used for its elaboration.
Identification of information on data sources and study variables.
The study population included patients with the disease under study: COPD.
Studies published in the last five years (January 1, 2015 - July 30, 2020).
Publications in English and Spanish.
Prior to conducting the literature search, a review protocol was developed that included a timeline, the research question, inclusion criteria for the articles to be selected and a table for extracting data from the studies. Figure 1 shows the procedure carried out, following the guidelines proposed in the PRISMA Guide . Thus, the selection process was divided into four parts: identification, screening, selection and inclusion. Identification was carried out by means of the research question in the different databases mentioned above. This phase yielded 359 results. After eliminating duplicate articles (n:233) and exploring the literature, we proceeded to the screening phase, in which the 126 titles of all articles (359–233) were examined and, following the aforementioned inclusion criteria, those that were considered not relevant were discarded (n:60). Those which were doubtful proceeded to the third phase (n:66). One of the limitations found and analyzed later lies in the high number of duplicated articles, probably due to a failure related to the level of hierarchy when establishing the combination between search terms. But nevertheless, to facilitate the management of the volume of articles, the selection phase was divided into two sub-phases; a preliminary phase in which the title and abstract of each of the studies were reviewed for mention of the target population of the study and the inclusion criteria were applied. In this manner, the 66 articles mentioned above were analyzed, after which 48 were discarded, subsequently, in a second phase the studies were assessed as eligible based on the full text. Finally, the remaining 18 articles were included in the review and are presented in this manuscript.
This review highlights the significant economic burden of COPD. Methodological heterogeneity was found in the studies included in the review. The different authors considered different variables to estimate direct healthcare costs, direct non-medical care costs, indirect costs and intangible costs, and even used different quantification methodologies and different economic conditions, currencies, and billing years. In addition, the variability among the different health systems in which the various studies included in this review are framed must also be considered. In summary, the studies used different approaches to estimate resource consumption. Although each method is valid and appropriate and there is no standard formula to be applied homogeneously in each study, the resources allocated to the disease were identified differently, which can generate disparities in the cost estimation.
This disparity leads to a wide variability of results for the cost of COPD disease. Each perspective provides useful and valid information on costs for a particular group (different samples with different patient sociodemographic and disease-related characteristics), although this makes comparison of results difficult.
First, the most relevant characteristics identified in the eighteen selected articles are presented. The studies selected in this systematic review included the following designs: cohort study (n = 11), systematic review (n = 5) and cross-sectional study (n = 2). These studies were published between 2016 and 2020, thus presenting the most updated data on the subject under study. The monograph is based on a global setting; therefore the analyzed articles were conducted mostly in Europe, but also Asia and America. One of the most important aspects when carrying out a cost study and analyzing its results is to identify the perspective presented by each study. Thus, the present systematic review is made up of studies with a societal perspective (9 articles), followed by the perspective of the National Health System (4 articles), that of the patient (1 article) and that of the public decision-maker (1 article). Finally, regarding the main objective of the research studies analyzed, most studies aim to evaluate the economic and social impact and burden of COPD in the different health systems and societies where the studies are conducted, as well as to identify the main factors that increase the cost of the disease. These are the same objectives sought by the present monograph. See Table 2.
As shown in Table 3 (methodological aspects of the articles), first, the variables used to estimate costs were identified. These were divided into several groups. Starting with those variables related to the sociodemographic characteristics of the patient and/or caregiver, mainly elements such as age, sex, smoking, employment status or socioeconomic status. Secondly, it is also important to highlight the presence, in most of the included studies, of variables that respond to patient characteristics related to the disease, mainly: GOLD stage, COPD severity, years of follow-up of the disease, respiratory symptoms or the CAT scale (COPD impact and quality of life test). This leads to the variables related to direct health care costs, mainly consisting of the costs of patients hospitalized for COPD and/or other causes, outpatient costs, drug costs or costs of visits to the emergency department. In relation to direct non-health costs, these mainly include the variables of the cost of home oxygen, medical transport, and informal care. Furthermore, there are variables that study indirect costs, in this case mainly related to loss of productivity and absenteeism, early retirement or premature mortality. Finally, we find the variables related to the study of intangible costs, where HRQOL and DALYs are identified.
This table shows the main limitations identified by the authors of the articles included in the monograph, with many of them agreeing on the difficulties identified. In summary, we can highlight the variability between countries (both in terms of patients and health services), cultural differences and differences in health practices, recall and selection bias (which can lead to an underestimation or overestimation of costs), difficulties in reaching the sample size, heterogeneity in designs between studies, differences in the level of COPD severity of the patients selected, and the non-inclusion of the costs of exacerbations in some of the articles. See Table 3.
As shown in Table 4, the direct healthcare costs (17 articles), are the most studied and are present or referred to in 17 out of 18 studies. These are followed by studies analyzing indirect costs (13 articles), direct non-health costs (8 articles) and finally, intangible costs (2 articles).
The main structure presented by most of the studies starts with an analysis of direct health costs, followed by direct costs unrelated to health, and finally by indirect costs. As traditionally occurs in cost-of-illness studies, the least studied costs were the intangible costs, since only 2 of the 18 studies included these in their research. This is possibly due to the lack of information and records and the difficulty of their evaluation, quantification, and subsequent analysis, since it is very difficult to create a monetary value for aspects such as health-related quality of life (HRQoL) or disability.
In short, the heterogeneity of the studies makes it difficult to compare results. In this regard, the cost varies greatly depending on the countries studied, whether they have public or private health systems and whether they are conducted in developed or developing countries. In conclusion, a great variability was found in the costs reported in the studies, where the total cost per COPD patient varies strikingly between geographically distant areas.
Starting with direct health care costs, the data are analyzed and presented for the different geographical areas studied. Thus, in Europe (the geographic area where most of the studies in this monograph are set), this cost ranges from high-cost areas such as Norway at €10,701 (€/2019) per patient per year and Belgium at €1963 (€/2019) per patient per year. The average cost established among eight European countries (Norway, Denmark, Germany, Italy, Sweden, Greece, Belgium, and Serbia) for total direct costs per patient per year is €6182 (€/2019) . Secondly, in the case of Asia, regarding the direct healthcare cost, no major significant differences were found among the developed Asian countries (Japan, South Korea, Singapore, Taiwan, and China). The average is estimated at approximately $9172 (USD/2017) . Finally, in the USA, the figures remain between $9981 (USD - N/A) and $6246 (USD/2010) .
Considering the indirect costs (the second most studied), starting again with Europe, Rehman et al. , in their recent published systematic review of European studies established that the loss of productivity was highest in Germany with €5735 and the lowest in Greece with €998. This productivity loss was estimated at €4824 in Bulgaria, €2033 in Denmark and €1298 in Sweden. In the case of Asian countries, the total annual social costs ranged from $4398 to $23,049 per capita in Japan and from $453 to $12,167 in South Korea, $2700 in Singapore, $4000 in Taiwan, $3942 in China, and $1105 in Thailand . Finally, Patel et al.  (2018) published in the USA that the loss of productivity was 5 more days/year of absence from work in patients with COPD and an increase in short-term disability of $641 compared to patients without the disease.
The following are direct non-health care costs, these types of costs are present in eight of the 18 articles analyzed in this review, many of which have already been included in the section on direct healthcare costs. There are some exceptions that report total direct costs, making no distinction between health and non-medical costs.
Finally, only two authors included intangible costs in their articles. In summary they established that patients with mild COPD spend 0.62 years of their life in disability, for those with moderate COPD this can represent as much as 6 years, and in the case of severe stages of the disease, this figure amounts to 9 years y reporting that the quality of life was worse among patients with COPD than in patients without COPD and also that they had a higher risk of depression during the course of the disease than patients who did not suffer from the disease. See Table 4.
Discussion and conclusions
COPD is one of the main chronic diseases identified in developed countries. The latest epidemiological data indicate a high growth rate, which is projected even more intensely into the future, mainly related to population aging and smoking, which is present in western societies with worrying figures. Its identified morbimortality is one of the factors that disrupts the economic stability of health institutions, which is one of the basic pillars of a nation, and consequently increases the costs attributable to society at large [1, 2].
Regarding the characteristics of the selected articles (Table 2) and their methodological aspects (Table 3), it is important to note that the variability of costs in the reported results are largely a consequence of methodological divergences and research objectives that impact the type of costs in the way existing resources are identified, measured, valued and consumed by COPD patients in the various study settings. This variability may also be due in part to real differences between countries, such as epidemiological differences, differences in the sociodemographic characteristics of the patients included in the analyses, the main characteristics of the health systems in each area and even differences in the prevention and treatment of COPD and its complications, as well as the way professionals work and cultural differences.
In the case of the economic characteristics of the selected articles (Table 4), one of the limitations found was that health cost studies report their results in different currencies (apart from some intangible cost studies). As this systematic review comprises worldwide studies, each study was conducted in a different geographical setting, consequently presenting its results in different currencies (euros, Indian rupee, Canadian dollar, or US dollar), as well as computing this value in different years, from 2010 for the oldest study to 2019 for the most recent. This, in turn makes it difficult to equate and compare results unanimously, which generates discrepancies and heterogeneity when presenting and reflecting on the results found. Secondly, the studies identified in this review clearly show that there are not many studies that simultaneously estimate direct healthcare costs, direct non-medical care costs and indirect costs. Only three authors carried out such a study [12, 14, 18]. The scarce presence of non-medical costs, which refer to items such as the costs derived from personal care (formal and informal) and the transport or subsistence costs required by the disease, is noteworthy. Less than half of the studies identified incorporated this item in some way, and if they did, in most cases they complemented healthcare costs. However, none of them included the family cost related to the care of persons as a consequence of the disease. Also, it is important to mention that some studies are based on the perspective of COPD cost calculation and others show the total attributable costs in COPD patients (in this case older patients) since the costs generated by the comorbidities and peculiarities of each patient in the study sample are also included.
In view of the objectives of this monograph, it is important to mention that the 18 cost studies identified in this systematic review indicate that COPD significantly increases overall economic costs, thus generating significantly higher excess costs for people with COPD, compared to people without the disease. Regarding the factors that increase costs in COPD patients, after reading and analyzing the 18 articles included in the review, the main link that leads to the greatest increase in costs in this pathology is AECOPD (acute exacerbation of COPD), the main complication, which occurs more frequently and is greater with more severe COPD and cases that are worse controlled. Thus, the patients who generate the most costs within the disease are those who are in a moderate-severe stage of the disease and who, in addition, have the worst control of their pathology. Poor control of respiratory disease in general, and specifically in the COPD patient, is based on poor adherence to treatment and a lack of skill or technique in carrying out the prescribed pharmacological treatment. This, together with the presence of other risk factors such as smoking or obesity and factors external to the patient, such as environmental conditions or aging, lead to an increase in the number of exacerbations, which in most cases can lead to visits to the emergency department or even hospitalizations that generate high costs, which, in addition to the patient’s own comorbidities, can be lengthy. These comorbidities are the second most present factor which the studies refer to the most regarding the increase in costs, since patients with a greater number of chronic diseases generate increased costs, due to a greater consumption of drugs, greater hospital and outpatient visits, the performance of greater functional and laboratory tests, and, directly and indirectly affecting parameters that make up work losses, increased disability, loss of HRQOL or the need for the presence of an informal caregiver to support the patient’s basic care.
Finally, a breakdown by type of cost shows that all the authors reached the consensus that the main components of direct healthcare costs are hospitalizations (produced in most cases by AECOPD) and medication to treat these complications, whereas in general the other components (medical visits, emergency visits, diagnostic tests) are less relevant. Likewise, regarding indirect costs, the studies identified highlight the importance that work losses can have as a consequence of the disease. These are reported by more than half of the authors included in the literature review. This aspect entails not only a loss for the employer or society as a whole, but also a direct impact on the economic stability of the individuals facing the disease and, consequently, also on their families or persons on whom their economic income depends.
In conclusion, given the importance of COPD, both for the health system and for society, it would be advisable to reassess the allocation of resources for the disease by taking into account the study of costs.
Availability of data and materials
The corresponding author on behalf of the other authors guarantee the accuracy, transparency and honesty of the data and information contained in the study, that no relevant information has been omitted and that all discrepancies between authors have been adequately resolved and described.
Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary Disease [Monograph on the Internet]. USA: Global Initiative for Chronic Obstructive Lung Disease; 2020 [Accessed Dec 15, 2020]. Available at : https://goldcopd.org/wpcontent/uploads/2019/12/GOLD-2020-FINAL-ver1.2-03Dec19_WMV.pdf
Grupo de trabajo de GesEPOC. Guía de Práctica Clínica para el Diagnóstico y Tratamiento de Pacientes con Enfermedad Pulmonar Obstructiva Crónica (EPOC) – Guía española de la EPOC (GesEPOC). Versión 2017. Arch Bronconeumol [Internet] 2017 junio [citado 20 diciembre 2020]; 53(1): 2–64. https://doi.org/10.1016/S0300-2896(12)70035-2.
González Del Castillo J, Candel FJ, de la Fuente Federico Gordo J et al. Manejo integral del paciente con exacerbación aguda de la enfermedad pulmonar. Rev Esq Quimioter [Internet] 2018 October [Accessed 20 Dec 2020]; 31(5):461–84. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6194861/
Cerezo-Lajas A, Rodríguez-Jimeno E, Gallo-González V et al. Mortalidad y factores asociados al reingreso en pacientes dados de alta tras una exacerbación aguda de EPOC. Rev Patol Respit [Internet] 2018 September [Accessed 22 Dec 2020]; 21(3):78–85. Available at: https://www.revistadepatologiarespiratoria.org/descargas/PR_21-3_79-85.pdf
Urrútia G, Bonfill X. Declaración PRISMA: una propuesta para mejorar la publicación de revisiones sistemáticas y metaanálisis. Med Clin (Barc) [Internet]. 2010 [Cited 28 Dec 2020];135(11):507–11. https://doi.org/10.1016/j.medcli.2010.01.015.
Foo J, Landis SH, Maskell J, et al. Continuing to Confront COPD International Patient Survey: Economic Impact of COPD in 12 Countries. PloS One [Internet]. 2016 [cited 8 Jan 2021];11(4):e0152618. https://doi.org/10.1371/journal.pone.0152618.
Wacker ME, Jorres RA, Schulz H, et al. Direct and indirect costs of COPD and its comorbidities: Results from the German COSYCONET study. Respir Med [Internet]. 2016 [Accessed 8 Jan 2021];111:39–46. https://doi.org/10.1016/j.rmed.2015.12.001.
Chen W, FitzGerald JM, Sin DD, et al. Excess economic burden of comorbidities in COPD: a 15 year population-based study. Eur Respir J [Internet]. 2017 [Accessed 8 Jan 2021];50:1700393. https://doi.org/10.1183/13993003.00393-2017.
Tachkov K, Kamusheva M, Pencheva V, Mitov K. Evaluation of the economic and social burdne of Chronic obstructive pulmonary disease (COPD). Biotechnol Biotechnol Equip [Internet]. 2017 [Accessed 8 Jan 2021];31(4):855–61. https://doi.org/10.1080/13102818.2017.1335616.
Wacker ME, Kitzing K, Jorres RA, et al. The contribution of symptoms and comorbidities to the economic impact of COPD: an analysis of the German COSYCONET cohot. Int J Chron Obstruct Pulmon Dis [Internet]. 2017 [Accessed 8 Jan, 2021];12:3437–48. https://doi.org/10.2147/COPD.S141852.
Quang Vo T, Ngoc Phung TC, Quoc Vu T, et al. Cost trend analysis of Chronic obstructive pulmonary disease among Vietnamese patients: Findings from two provincial facilities 2015-2017. J Clin Diagn Res [Internet]. 2018 [Accessed 8 Jan 2021];12(6):LC92–8. https://doi.org/10.7860/JCDR/2018/36668.11715.
Lakiang T, Nair NS, Ramaswamy A, et al. Economic impact of Chronic obstructive pulmonary disease: A cross-sectional study at teaching hospital in South India. J Family Med Prim Care [Internet]. 2018 [Accessed 8 Jan 2021];7:1002–6. https://doi.org/10.4103/jfmpc.jfmpc_75_16.
Lisspers K, Larsson K, Johansson G, et al. Economic burden of COPD in a Swedish cohort: the ARCTIC study. Int J Chron Obstruct Pulmon Dis [Internet]. 2018 [Accessed 8 Jan 2021];13:275–85. https://doi.org/10.2147/COPD.S149633.
Merino M, Villoro R, Hidalgo-Vega A, et al. Social economic costs of COPD in Extremadura (Spain): an observational study. Int J Chron Obstruct Pulmon Dis [Internet]. 2018 [Accessed 9 Jan 2021];13:2501–14. https://doi.org/10.2147/COPD.S167357.
Patel JG, Coutinho AD, Lunacsek OE, et al. COPD affects worker productivity and health care costs. Int J Chron Obstruct Pulmon Dis [Internet]. 2018 [Accessed 9 Jan 2021];13:2301–11. https://doi.org/10.2147/COPD.S163795.
Stafyla E, Geitona M, Kerenidi T, et al. The annual direct costs of stable COPD in Greece. Int J Chron Obstruct Pulmon Dis [Internet]. 2018 [Accessed January 9, 2021];13:309–15. https://doi.org/10.2147/COPD.S148051.
Zhu B, Wang Y, Ming J, et al. Disease burden of COPD in China: a systematic review. Int J Chron Obstruct Pulmon Dis [Internet]. 2018 [Accessed 9 Jan 2021];13:1353–64. https://doi.org/10.2147/COPD.S161555.
Changhwan Kim MD, Younhee Kim PD, Dong-Wook Yang PD, et al. Direct and indirect costs of Chronic obstructive pulmonary disease in Korea. Tuberc Respir Dis (Seoul) [Internet]. 2019 [Accessed 9 Jan 2021];82(1):27–34. https://doi.org/10.4046/trd.2018.0035.
Rehman AU, Admad Hassali MA, Ayaz Muhammad S, et al. The economic burden of Chronic obstructive pulmonary disease (COPD) in the USA, Europe, and Asia: results from a systematic review of the literature. Expert Rev Pharmacoecon Outcomes Res [Internet]. 2019 [Accessed 9 Jan 2021];18:1–12. https://doi.org/10.1080/14737167.2020.1678385.
Viinanen A, Lassenius MI, Toppila I, et al. The burden of Chronic obstructive pulmonary disease (COPD) in Finland: Impact of disease severity and eosinophil count on healthcare resource utilization. Int J Chron Obstruct Pulmon Dis [Internet]. 2019 [Accessed 10 Jan 2021];14:2409–21. https://doi.org/10.2147/COPD.S222581.
Woo L, Smith HE, Sullivan SD. The economic burden of Chronic obstructive pulmonary disease in the Asia-Pacific Region: A systematic review. Value Health Reg Issues [Internet]. 2019 [Accessed 10 Jan 2021];18:121–31. https://doi.org/10.1016/j.vhri.2019.02.002.
Iheanacho I, Zhang S, King D, et al. Economic burden of Chronic obstructive pulmonary disease (COPD): A systematic literature review. Int J Chron Obstruct Pulmon Dis [Internet]. 2020 [Accessed 10 Jan 2021];15:439–60. https://doi.org/10.2147/COPD.S234942.
Rehman AU, Ahmad Hassali MA, Ayaz Muhammad S, et al. The economic burden of Chronic obstructive pulmonary disease (COPD) in Europe: results from a systematic review of the literature. Eur J Health Econ [Internet]. 2020 [Accessed 10 Jan 2021];21(2):181–94. https://doi.org/10.1007/s10198-019-01119-1.
This research has been carried out without funding.
Ethics approval and consent to participate
Consent for publication
All authors have approved the final version of the manuscript.
The authors declare no conflict of interest.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Gutiérrez Villegas, C., Paz-Zulueta, M., Herrero-Montes, M. et al. Cost analysis of chronic obstructive pulmonary disease (COPD): a systematic review. Health Econ Rev 11, 31 (2021). https://doi.org/10.1186/s13561-021-00329-9
- Systematic review
- Pulmonary disease
- Chronic obstructive
- Cost of illness
- Health care costs